BofA raises Linde stock price target on higher 2026 earnings

BofA Securities raised Linde’s price target to $532 from $525 and kept a Buy rating, while JPMorgan and BMO also lifted targets to $530 and $560, respectively. BofA nudged its 2026 EPS estimate up to $17.88 from $17.86, roughly in line with the $17.90 consensus, though the outlook is tempered by a delayed Woodside project commissioning into 2027. Linde also beat Q1 estimates with adjusted EPS of $4.33 versus $4.27 consensus and revenue of $8.78 billion versus $8.6 billion, alongside a 34-year streak of dividend increases.

Analysis

The market is still treating LIN like a defensive quality compounder, but the real issue is duration: this is a long-cycle industrial story where near-term execution noise is getting capitalized too generously. A modestly lower discount rate matters, but the bigger takeaway is that consensus is already close to the updated 2026 number, so upside now depends on 2027 delivery and project timing rather than earnings momentum. That makes the stock vulnerable to multiple compression if rates stop falling or if project slippage becomes a recurring pattern rather than a one-off.

Second-order beneficiaries are not the obvious large-cap industrials, but peers with more exposed pricing reset leverage and shorter project cycles. If Linde’s mix of buybacks, currency help, and delayed capex still only supports mid-single-digit EPS growth, then the market may start rewarding names where incremental capital turns into cash flow faster. For competitors and adjacent suppliers, any prolonged pushout in large air-separation and gas infrastructure work can temporarily tighten engineering and construction capacity, which is mildly positive for the subcontracting ecosystem but negative for equipment names dependent on timely LNG/chemicals project conversion.

The contrarian read is that the stock may not be cheap, but it may be misframed: investors are paying for capital discipline and resilience, not just growth. That said, the valuation support weakens if the next two quarters fail to show a cleaner path from backlog to revenue, because the multiple is already discounting a high-quality compounding profile. In that scenario, the downside is less about earnings misses and more about the market deciding this is a bond proxy with limited upside in a stable-rate environment.

Key Decisions for Investors

• Tactically trim/add-to-short: reduce LIN exposure on strength above the prior high zone; use a 3-6 month horizon. Risk/reward is poor if 2027 project slippage keeps pushing out cash conversion, while downside should accelerate if the market re-rates quality defensives lower on a higher-for-longer rate path.
• Pair trade: long APD / short LIN for 3-9 months. APD offers more visible operating leverage to industrial recovery while LIN’s valuation already reflects quality; the pair isolates execution upside versus crowded defensive ownership.
• If holding LIN, finance upside with an out-of-the-money call overwrite 2-4 months out. This monetizes premium while capping limited near-term appreciation, which seems appropriate given consensus is already close to the updated earnings view.
• Watch for a re-entry only on a pullback into a lower multiple regime or after a clearly de-risked project update. At current levels, the setup favors patience over initiation unless long-only mandates require a core defensive compounder.
• For event-driven accounts, consider short-dated put spreads around the next guidance update. The catalyst is not an earnings collapse, but a disappointment in sequencing or capex timing that could compress the multiple faster than earnings estimates move.